Determining the Structure of Nuclear Receptor has Implications for a Host of Diseases
News Sep 18, 2008
Van Andel Institute (VAI) researchers have determined the molecular structure of a nuclear receptor, which regulates the expression of specific genes within cells, that may serve as a drug target for diseases related to heart and blood vessel development, human embryonic development and female infertility. Researchers also found that the receptor, named COUP-TFII, is activated by retinoic acid, a form of Vitamin A.
“Not only does the structural information provide a basis for drug design in any diseases that COUP-TFII plays a role in, but it also can provide insight into the entire subfamily of receptors that COUP-TFII belongs to, which could have implications for additional associated diseases,” said VAI Distinguished Scientific Investigator Eric Xu, Ph.D., who heads the laboratory that published the findings in PLoS Biology.
VAI researchers determined the molecular structure of COUP-TFII through X-ray crystallography, which involved purifying the protein, growing crystals, directing X-rays at the crystals, and using the resulting information to determine the structure. Structural information can help drug developers fit therapeutics more perfectly to the receptors they bind to for maximum potency and can also aid in manipulating drugs to produce fewer side effects.
The findings could also have implications for cancer therapy. “Since COUP-TFII plays a role in embryonic blood vessel development, it might play a similar role in tumors and cancer growth,” said Schoen Kruse, Ph.D., lead author of the study and former postdoctoral fellow at VAI. “Formation of new blood supply in tumors is a stepping stone in the ability of cancers to grow and metastasize within the body.” Kruse is now an Assistant Professor in the Department of Pharmacology at Rocky Vista University, College of Osteopathic Medicine.
The signal-triggering molecules known as ligands, which activate nuclear receptors have been discovered for most receptors. The study’s finding that COUP-TFII is activated by retinoic acid is significant since the receptor previously belonged to a subset of “orphan” nuclear receptors whose ligands are unknown.
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE